

## TX CLINICAL CRITERIA & PROCEDURE

<b>CRITERIA NAME:</b> Velmanase alfa-tycv (Lamzede)	<b>CRITERIA ID:</b> TX.CC.PHAR.40
<b>BUSINESS UNIT:</b> Superior HealthPlan	<b>FUNCTIONAL AREA:</b> Pharmacy, Medical Directors
<b>EFFECTIVE DATE:</b> 08/01/2024	<b>PRODUCT(S):</b> STAR, STAR Health, STAR Kids, Star Plus, CHIP, CHIP Perinate
<b>REVIEWED/REVISED DATE:</b> 6/2/2025	<b>REGULATOR MOST RECENT APPROVAL DATE(S):</b> N/A

### CRITERIA STATEMENT:

The purpose of this clinical criteria is to provide a guide to medical necessity reviews for velmanase alfa-tycv (Lamzede).

### PURPOSE:

Consistent with the regulation at 42 CFR Section 438.210 and 42 CFR Section 457.1230(d), services covered under managed care contracts, including clinician-administered drugs, must be furnished in an amount, duration, and scope that is no less than the amount, duration, and scope for the same services specified in the state plan. While MCOs may place appropriate limits on drugs, MCOs may not use a standard for determining medical necessity that is more restrictive than what is used in the state plan, i.e., developed by the Vendor Drug Program. For example, if a member is denied a clinician administered drug in managed care because of the MCO's prior authorization criteria, but would have received the drug under the criteria specified in the state plan, then the MCO's prior authorization criteria would violate the amount, duration, and scope requirements cited above. HHSC intends to amend the Managed Care Contracts at the next opportunity to include this requirement. This same standard applies to CHIP formulary and CAD coverage.

Refer to the Outpatient Drug Services Handbook of the Texas Medicaid Provider Procedure Manual for more details on the clinical criteria and prior authorization requirements.

This medication is a non-risk based (NRB) payment drug and should follow state guidance for medical necessity review for Medicaid/CHIP due to the manner in which it is reimbursed. All determinations will be performed by a Medical Director. A pharmacy clinician will review the prior authorization request and make a recommendation to the Medical Director but will not make the ultimate determination on any case.

### SCOPE:

This criteria applies to all directors, officers, and employees of Centene Corporation, its affiliates, health plans, and subsidiary companies (collectively, the "Company").

**DEFINITIONS:** N/A

### POLICY:

It is the policy of Superior HealthPlan (SHP) and Centene Pharmacy Services (CPS) to follow state guidance for medical necessity review of velmanase alfa-tycv (Lamzede); procedure code: J0217.

### PROCEDURE:

*Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria.*

## I. Initial Approval Criteria

### A. FDA Approved Indications

1. A Medical Director is required to review and approve or deny all requests. A pharmacy clinician will make a recommendation on the prior authorization, but ultimate determination will be made by the Medical Director only.
2. Prior authorization approval for Lamzede (velmanase alfa-tycv) will be considered when all the following criteria are met and documentation must include:
  - a. A request for the specific enzyme replacement therapy
  - b. The laboratory evidence of the enzyme deficiency (*See Appendix A for examples of applicable diagnostic confirming labs*)
  - c. Client has a diagnosis of non-central nervous system manifestation of alpha-mannosidosis (diagnosis code: E77.1)
  - d. Verification of pregnancy status for female clients of reproductive potential prior to therapy initiation

**Approval duration: 6 months**

### Appendix A.

Enzyme replacement therapy	Indication	Diagnostic Lab Examples
Velmanase alfa-tycv (Lamzede)	Alpha-Mannosidosis	Reduced AM activity defined as < 10% of normal activity in leukocytes or fibroblasts cells OR genetic testing revealing biallelic MAN2B1 gene mutation

#### REFERENCES:

Texas Medicaid Provider Procedure Manual: Outpatient Drug Services Handbook

**ATTACHMENTS:** N/A

#### REVISION LOG

REVISION TYPE	REVISION SUMMARY	DATE APPROVED & PUBLISHED
New Policy	Created TX.CC.PHAR.40 Lamzede criteria taken from TX.CC.PHAR.33 Created separate criteria for Lamzede ERT (from TX.CC.PHAR.33) to address Lamzede NRB status	8/1/2024
Annual review	Font and formatting updates made for 508 remediation	6/2/2025

©2024 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.